| Company Name: |
Zhengzhou Convergence Chemical Co. LTD
|
| Tel: |
0371-53736046 13393710386 |
| Email: |
2853979814@qq.com |
| Products Intro: |
Product Name:Acetamide, 2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-
CAS:2248703-42-4
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:SACLAC
CAS:2248703-42-4
Purity:98%+ HPLC Package:10mg，500mg，1g，2g，5g，10g，more
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:SACLAC
CAS:2248703-42-4
Purity:95% Package:1mg;5mg;10mg
|
| Company Name: |
Wuhan Acumen Bio-Technology Co.,ltd
|
| Tel: |
027-027-16602739303 16602739303 |
| Email: |
673003916@qq.com |
| Products Intro: |
Product Name:Acetamide, 2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-
CAS:2248703-42-4
Purity:95% HPLC Package:5G;1G
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:SACLAC；
CAS:2248703-42-4
Purity:具体详见官网信息 Package:详见官网
|
|
| | Acetamide, 2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]- Basic information |
| | Acetamide, 2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]- Chemical Properties |
| Boiling point | 560.1±50.0 °C(Predicted) | | density | 1.016±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Chloroform: soluble | | form | A solid | | pka | 13.01±0.46(Predicted) |
| | Acetamide, 2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]- Usage And Synthesis |
| Biological Activity | SACLAC is an irreversible inhibitor of acid ceramidase (Ki = 97.1 nM) and a derivative of the acid ceramidase inhibitor SABRAC .1 It decreases levels of sphingosine-1-phosphate (S1P) and increases total ceramide levels in OCI-AML-2 acute myeloid leukemia (AML) cells when used at a concentration of 2.5 μM.2 SACLAC (10 and 20 μM) induces apoptosis in primary AML cells. It reduces leukemic burden in MV4-11 and U937 AML mouse xenograft models when administered at a dose of 5 mg/kg. | | References | 1.Ordó?ez, Y.F., Abad, J.L., Aseeri, M., et al.Activity-based imaging of acid ceramidase in living cellsJ. Am. Chem. Soc.141(19)7736-7742(2019)
2.Pearson, J.M., Tan, S.-F., Sharma, A., et al.Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemiaMol. Cancer Res.18(3)352-363(2020) |
| | Acetamide, 2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]- Preparation Products And Raw materials |
|